Enovis Outperforms Rennova Health in Financial Comparison

Analysis shows Enovis has stronger financials, lower volatility, and more favorable analyst ratings compared to Rennova Health.

Published on Mar. 2, 2026

Got story updates? Submit your updates here. ›

A financial comparison between medical companies Enovis (NYSE:ENOV) and Rennova Health (OTCMKTS:RNVA) reveals that Enovis outperforms Rennova Health across several key metrics, including revenue, earnings, volatility, institutional ownership, and analyst ratings.

Why it matters

This analysis provides investors with valuable insights to help them make informed decisions when evaluating these two small-cap medical companies as potential investment opportunities.

The details

Enovis has a beta of 1.52, indicating its stock price is 52% more volatile than the S&P 500, while Rennova Health has a much higher beta of 22.39, meaning its stock is over 21 times more volatile. In terms of financials, Enovis has higher revenue and earnings per share compared to Rennova Health. Enovis also has stronger net margins, return on equity, and return on assets. Additionally, Enovis has significantly higher institutional ownership at 98.5% versus just 20.2% for Rennova Health, suggesting greater confidence from large investors. Analysts also have a more favorable view of Enovis, with a consensus price target implying 86% upside potential, compared to Rennova Health.

  • The financial data and analysis is current as of March 1, 2026.

The players

Enovis Corporation

A medical technology company that develops clinically differentiated solutions for reconstructive surgery, rehabilitation, pain management, and physical therapy.

Rennova Health, Inc.

A healthcare services provider that owns one operating hospital in Tennessee and a rural clinic in Kentucky.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights Enovis' stronger financial position, lower volatility, and more favorable analyst ratings compared to Rennova Health, making it the more attractive investment option between the two small-cap medical companies.